Microbix Biosystms (TSE:MBX) has released an update.
Microbix Biosystems Inc., a life sciences company, has supported Labquality Ltd. in establishing a new lab accreditation program for molecular tests of drug-resistant sexually-transmitted infections, specifically M. genitalium. Their Quality Assessment Products have proven effective in a pilot program that assessed the proficiency of 38 clinical labs, confirming the need for such external quality assessments in testing. The promising results and availability of Microbix’s innovative control products were showcased at the ECCMID 2024 conference in Barcelona.
For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.
